Fluvastatin Sodium
FDA-approved product (capsule, oral), marketed as Fluvastatin Sodium, Lescol, Lescol Xl.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cardiovascular disease
- Familial hypercholesterolemia
- Hypercholesterolemia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Hmg coa reductase inhibitors
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA47.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli27.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae18.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis59.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Fluvastatin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass
NCT00489424 · start 2007-06
Registered record
- Registry ID
- NCT00489424
- Conditions
- Osteoporosis
- Interventions
- Placebo; Acetaminophen; Fluvastatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2007-06
- Completion
- 2007-12
- Enrolment
- 793
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOsteoporosisInterventionPlacebo; Acetaminophen; FluvastatinPhasePhase 4Registry statusCompletedImprovement of Erectile Dysfunction by Fluvastatin in Patients With Cardiovascular Risk Factors
NCT00382161 · start 2006-10
Registered record
- Registry ID
- NCT00382161
- Conditions
- Impotence
- Interventions
- Fluvastatin-sodium
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Withdrawn
- Start
- 2006-10
- Completion
- 2007-12
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionImpotenceInterventionFluvastatin-sodiumPhasePhase 3Registry statusWithdrawnIntensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension
NCT00407680 · start 2006-10
Registered record
- Registry ID
- NCT00407680
- Conditions
- Type 2 Diabetes Mellitus; Hypertension
- Interventions
- Intensive therapy Valsartan,Fluvastatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2006-10
- Completion
- 2009-03
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionType 2 Diabetes Mellitus; HypertensionInterventionIntensive therapy Valsartan,FluvastatinPhasePhase 4Registry statusUnknownFluvastatin Versus Hepatitis C Virus
NCT00441493 · start 2006-09
Registered record
- Registry ID
- NCT00441493
- Conditions
- Hepatitis C
- Interventions
- fluvastatin
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2006-09
- Completion
- 2007-09
- Enrolment
- 32
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatitis CInterventionfluvastatinPhaseNot applicableRegistry statusCompletedThe Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome
NCT00664742 · start 2006-09
Registered record
- Registry ID
- NCT00664742
- Conditions
- Metabolic Syndrome
- Interventions
- Fluvastatin XL®
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2006-09
- Completion
- 2007-10
- Enrolment
- 614
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMetabolic SyndromeInterventionFluvastatin XL®PhasePhase 4Registry statusCompletedReducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome
NCT00821574 · start 2005-07
Registered record
- Registry ID
- NCT00821574
- Conditions
- Hypertension, Dyslypidaemia
- Interventions
- Fluvastatin; Valsartan; Hydrochlorothiazide
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2005-07
- Completion
- 2007-03
- Enrolment
- 144
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertension, DyslypidaemiaInterventionFluvastatin; Valsartan; HydrochlorothiazidePhasePhase 4Registry statusCompletedEfficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia
NCT00136799 · start 2005-06
Registered record
- Registry ID
- NCT00136799
- Conditions
- Mixed Dyslipidemia; Hypercholesterolemia
- Interventions
- Fluvastatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-06
- Completion
- 2006-04
- Enrolment
- 325
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMixed Dyslipidemia; HypercholesterolemiaInterventionFluvastatinPhasePhase 3Registry statusCompletedFluvastatin in Adults With Dislipidemia With History of Muscle Problems
NCT00125125 · start 2005-05
Registered record
- Registry ID
- NCT00125125
- Conditions
- Dyslipidemia
- Interventions
- Fluvastatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2005-05
- Completion
- 2005-12
- Enrolment
- 218
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDyslipidemiaInterventionFluvastatinPhasePhase 4Registry statusCompletedPolymorphism of the Cytochrome P450-system in Renal Transplants
NCT00223054 · start 2005-03
Registered record
- Registry ID
- NCT00223054
- Conditions
- Function of Renal Transplant
- Interventions
- tacrolimus; sirolimus; everolimus; cyclosporin A
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2005-03
- Completion
- 2006-10
- Enrolment
- 200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFunction of Renal TransplantInterventiontacrolimus; sirolimus; everolimus; cyclosporin APhaseNot recordedRegistry statusCompletedA 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)
NCT00132717 · start 2005-01-01
Registered record
- Registry ID
- NCT00132717
- Conditions
- Hypercholesterolemia
- Interventions
- MK0653A (ezetimibe [+] simvastatin); Comparator: atorvastatin; Comparator: fluvastatin; Comparator: lovastatin; Comparator: pravastatin; Comparator: rosuvastatin; Comparator: simvastatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-01-01
- Completion
- 2007-06-01
- Enrolment
- 450
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypercholesterolemiaInterventionMK0653A (ezetimibe [+] simvastatin); Comparator: atorvastatin; Comparator: fluvastatin; Comparator: lovastatin +3 morePhasePhase 3Registry statusCompletedFluvastatin After Heart Transplantation
NCT00421005 · start 2004-11
Registered record
- Registry ID
- NCT00421005
- Conditions
- Heart Transplantation; Hypercholesterolemia
- Interventions
- fluvastatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2004-11
- Completion
- 2008-11
- Enrolment
- 56
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHeart Transplantation; HypercholesterolemiaInterventionfluvastatinPhasePhase 4Registry statusUnknownOther Effects of Fluvastatin Are Investigated in Patients With Metabolic Syndrome
NCT00138528 · start 2004-10
Registered record
- Registry ID
- NCT00138528
- Conditions
- Metabolic Syndrome
- Interventions
- Fluvastatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2004-10
- Completion
- 2006-02
- Enrolment
- 55
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMetabolic SyndromeInterventionFluvastatinPhasePhase 4Registry statusCompletedTrial to Evaluate the Efficacy of Fluvastatin on Certain Markers
NCT00171262 · start 2004-08
Registered record
- Registry ID
- NCT00171262
- Conditions
- Dyslipidemia
- Interventions
- Fluvastatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2004-08
- Completion
- 2007-06
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDyslipidemiaInterventionFluvastatinPhasePhase 4Registry statusCompletedEfficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction
NCT00171327 · start 2004-07
Registered record
- Registry ID
- NCT00171327
- Conditions
- Hypertension; Dyslipidemia
- Interventions
- valsartan, fluvastatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2004-07
- Completion
- 2005-09
- Enrolment
- 213
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertension; DyslipidemiaInterventionvalsartan, fluvastatinPhasePhase 4Registry statusCompletedInvestigation of the Steady State Pharmacokinetics of Tacrolimus, Mycophenolate Mofetil and Fluvastatin After Renal Transplantation
NCT00223015 · start 2004-05
Registered record
- Registry ID
- NCT00223015
- Conditions
- Renal Transplantation
- Interventions
- Fluvastatin, Tacrolimus, Mycophenolat Mofetil
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2004-05
- Completion
- 2005-04
- Enrolment
- 15
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRenal TransplantationInterventionFluvastatin, Tacrolimus, Mycophenolat MofetilPhasePhase 4Registry statusCompleted